Comparing laparoscopic surgery outcomes for gastrointestinal stromal tumors based on tumor location
Official title: Prospective Controlled Clinical Trial for Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site（FUGES-016）
Run by Fujian Medical University · NCT03716089 · Data updated 2026-11-12
This study is testing how well laparoscopic surgery works for people with gastrointestinal stromal tumors based on where the tumors are located in the body.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Fujian Medical University Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Status | Recruiting |
| Started | October 11, 2018 |
| Main results expected | April 1, 2027 |
| Study ends | April 1, 2027 |
| Registry record updated | April 8, 2025 |
| Trial ID | NCT03716089 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 75 with a primary gastric GIST confirmed by biopsy and suitable for laparoscopic resection.
✕Probably not a fit
Patients with a history of severe mental disorders, previous upper abdominal or gastric surgeries, or those who reject laparoscopic resection may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the postoperative morbidity and mortality rates of laparoscopic resection for gastrointestinal stromal tumors (GIST) based on whether the tumors are located in favorable or unfavorable anatomical sites. Participants aged 18 to 75 with confirmed GIST will undergo laparoscopic surgery, and their outcomes will be monitored to determine the effectiveness of the procedure. The primary endpoint is the 3-year disease-free survival rate, which will help validate the safety and efficacy of this surgical approach in different tumor locations.
Why it matters
Potential benefit: If successful, this study could provide insights into optimizing surgical approaches for GIST, potentially improving patient outcomes.
How similar studies have gone: While there have been studies on laparoscopic resection for GIST, this specific comparison based on tumor site is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age between 18 and 75 years old 2. Primary gastric lesion confirmed pathologically GIST by endoscopic biopsy. Preoperative endoscopy, ultrasound endoscopy or computer tomography, Magnetic resonance suspected GIST, and then postoperative pathology confirmed as the original GIST 3. Written informed consent 4. Expected R0 resection by laparoscopy 5. Performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) scale 6. ASA (American Society of Anesthesiology) class I to III 7. Maximum tumor diameter ≤10cm Exclusion Criteria: 1. Pregnant and lactating women 2. Suffering from a severe mental disorder 3. History of previous upper abdominal surgery (except for laparoscopic cholecystectomy) 4. History of previous gastric surgery (including ESD/EMR for gastric cancer) 5. Rejection of laparoscopic resection 6. History of other malignant disease within the past five years 7. History of unstable angina or myocardial infarction within the past six months 8. History of a cerebrovascular accident within the past six months 9. History of continuous systematic administration of corticosteroids within one month 10. Requirement of simultaneous surgery for another disease 11. Emergency surgery due to complications (bleeding, obstruction or perforation) caused by gastric cancer 12. FEV1\<50% of the predicted values 13. Maximum tumor diameter \>10cm
Where it's running
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.